CyborD-DARA combination in first-line treatment for multiple myeloma

CyborD-DARA combination in first-line treatment for multiple myeloma

CyborD-DARA combination in first-line treatment for multiple myeloma

Michael O’Dwyer, MD, PhD, from the National University of Ireland, Galway, Ireland, discusses the advantages of bringing daratumumab in the first-line setting as the CyborD-DARA combination ( cyclophosphamide, bortezomib and dexamethasone with daratumumab), for the treatment of multiple myeloma. Here, Prof. O’ Dwyer highlights that cyclophosphamide can activate macrophages, and therefore enhance antibody-dependent cellular phagocytosis. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

Leave a Reply

Your email address will not be published.